Overview

Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).

Phase:

Phase 3

Details

Lead Sponsor:

Medical University of South Carolina

Collaborator:

National Institute on Drug Abuse (NIDA)

Treatments:

Acetylcysteine
N-monoacetylcystine